4 completed. 4 Phase 3.
By phase and status
Follow Chronic Lymphocytic Leukemia (CLL): new trials by email Literature Review of Chronic Lymphocytic Leukemia (CLL) trials Research Report on Chronic Lymphocytic Leukemia (CLL)
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) Phase 3 Completed 166 2020-05-28 2026-03-03 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Obinutuzumab, Bendamustine, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Phase 3 Completed 120 2018-08-10 2024-08-06 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Venetoclax - Chronic Lymphocytic Leukemia (CLL) Phase 3 Completed 210 2016-12-13 2023-02-22 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Dinaciclib, Ofatumumab - Chronic Lymphocytic Leukemia (CLL) Phase 3 Completed 44 2012-08-01 2017-02-23
Narrower conditions Leukemia, Lymphocytic, Chronic, B-Cell (4) · Chromosome 17 deletion (2) · Neoplasms (1) · Tumor Lysis Syndrome (1)
Broader conditions Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, B-Cell (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Neoplasms (3)
Interventions venetoclax (3) · Bendamustine Hydrochloride (2) · obinutuzumab (2) · Cyclophosphamide (1) · Rituximab (1) · dinaciclib (1) · fludarabine (1) · ofatumumab (1)
Sponsors AbbVie (2) · Hoffmann-La Roche (1) · Merck Sharp & Dohme LLC (1)
Countries Australia (2) · United States (2) · Argentina (1) · Bulgaria (1) · France (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Mexico (1) · New Zealand (1) · Poland (1) · Russia (1) · Spain (1) · Taiwan (1)
Results publications PMID 28126927 , PMID 34632935 , PMID 41770817
NIH funding 2016 (1) , 2019 (1) , 2023 (1)